Key Takeaways Stelara sales dropped 42.7% in Q2 2025 as biosimilars hit the drug's sales hard.J&J expects over $57B in 2025 Innovative Medicines sales, roughly flat with 2024 despite Stelara LOE.Darzalex, Tremfya, Spravato, Erleada and new cancer drugs are driving double-digit growth for J&J.Johnson & Johnson’s (JNJ) multibillion-dollar immunology drug, Stelara, lost patent exclusivity in the United States this year. It is approved for treating moderate-to-severe plaque psoriasis, active psoriatic arthritis ...